Reclast (Zoledronic Acid) Cost in North Dakota: 2026 Pricing, Insurance, and Savings Guide

What Does Reclast (Zoledronic Acid) Actually Cost in North Dakota?

The sticker price and the price you pay are rarely the same drug. Novartis lists Reclast at roughly $1,500 per infusion, but the average cash-pay price across North Dakota retail pharmacies sits near $600 in 2026. Generic zoledronic acid formulations can bring that number lower still, depending on the dispensing facility and whether an infusion center or hospital outpatient department administers the drug.

Manufacturer List Price vs. Cash-Pay Reality

The $1,500 figure represents the wholesale acquisition cost (WAC) that Novartis and generic manufacturers set before any rebates or negotiated discounts. North Dakota's smaller pharmacy market means fewer infusion sites compete for patients, yet the average cash-pay price of $600 reflects the broader generic pricing pressure that has driven costs down nationally since zoledronic acid lost patent exclusivity. A 2020 analysis in the Journal of Bone and Mineral Research found that generic entry reduced per-infusion spending by 38% to 52% within three years of approval.

Facility Fee Variables

Where you receive your infusion matters as much as the drug price itself. Hospital outpatient departments in Fargo or Bismarck typically bill a facility fee on top of the drug cost, sometimes adding $200 to $500 to the total. Independent infusion centers or physician offices that buy-and-bill the drug can offer lower all-in pricing. Ask for an itemized estimate before scheduling.

Year-Over-Year Trend

Zoledronic acid pricing has remained relatively stable since 2023. The FDA's Orange Book lists multiple approved ANDA holders for the 5 mg/100 mL formulation, keeping generic competition active and price increases modest.

Why Zoledronic Acid Costs What It Does

Zoledronic acid is a once-yearly intravenous bisphosphonate. That dosing schedule means you pay for one infusion instead of 12 monthly prescriptions or 52 weekly tablets, but the single price tag can look high compared to oral bisphosphonates like alendronate, which runs $10 to $30 per month as a generic. The total annual cost, though, is often comparable or lower.

The HORIZON-PFT Evidence Behind the Price

The landmark HORIZON Key Fracture Trial (HORIZON-PFT, N=7,765) demonstrated that a single annual 5 mg IV infusion of zoledronic acid reduced the risk of vertebral fractures by 70%, hip fractures by 41%, and nonvertebral fractures by 25% over three years compared with placebo (Black et al., NEJM 2007) [1]. That efficacy profile is what supports both FDA approval and insurance coverage decisions. Payers view the once-yearly adherence advantage as a cost-offset: patients who miss weekly oral bisphosphonate doses lose fracture protection, generating downstream hospitalization costs.

Cost-Effectiveness Data

A 2019 systematic review published in Osteoporosis International concluded that zoledronic acid was cost-effective at thresholds of $50,000 per quality-adjusted life year (QALY) in women aged 65 and older with documented osteoporosis (Defined Daily Dose analysis, Hiligsmann et al.) [2]. For North Dakota patients weighing annual infusion cost against daily or weekly pill regimens, the math often favors the IV route when adherence history is poor.

North Dakota Medicaid and Reclast: Current Coverage Status

North Dakota Medicaid does not cover Reclast (zoledronic acid) for osteoporosis as of 2026. This applies to both the brand-name product and generic equivalents administered in outpatient settings.

Why the Coverage Gap Exists

State Medicaid formularies operate under the Medicaid Drug Rebate Program, but individual states retain discretion over preferred drug lists (PDLs). North Dakota's PDL currently directs osteoporosis treatment toward oral bisphosphonates (alendronate, risedronate) and denosumab as first-line and second-line options. Zoledronic acid falls into a non-preferred or non-covered tier, meaning a prescriber would need to pursue an exception or prior authorization with limited likelihood of approval.

What Medicaid Beneficiaries Can Do

If you are on North Dakota Medicaid and your physician believes zoledronic acid is medically necessary (for example, because you cannot tolerate oral bisphosphonates or have documented GI contraindications), three paths exist:

• Exception request. Your prescriber submits clinical documentation to North Dakota Medicaid explaining why preferred agents failed or are contraindicated. Approval rates for bisphosphonate-class exceptions vary, but GI intolerance is a recognized criterion under most state Medicaid programs.
• 340B pricing. Federally qualified health centers (FQHCs) and certain hospitals in North Dakota participate in the 340B Drug Pricing Program, which can reduce the acquisition cost of zoledronic acid dramatically. If you receive care at a 340B-covered entity, ask whether the infusion can be billed under that program.
• Manufacturer assistance. Novartis offers patient assistance programs (PAPs) for uninsured and underinsured patients. Eligibility is income-based, generally at or below 400% of the federal poverty level.

Insurance Coverage for Reclast in North Dakota

Most commercial insurance plans and Medicare Part B cover zoledronic acid for osteoporosis, though the specifics of cost-sharing and prior authorization requirements differ.

Medicare Part B

Because zoledronic acid is physician-administered via IV infusion, it falls under Medicare Part B rather than Part D. Part B typically covers 80% of the Medicare-approved amount after the annual deductible ($257 in 2026). Your out-of-pocket share for a single infusion often lands between $100 and $200 if you have original Medicare without supplemental coverage. Medigap plans (Plans C, F, or G) can reduce or eliminate that copay. The CMS Medicare Coverage Database provides the most current local coverage determination (LCD) for your region.

Commercial Plans (BCBS ND, Sanford Health Plan, Medica)

Blue Cross Blue Shield of North Dakota, Sanford Health Plan, and Medica are the dominant commercial carriers in the state. All three generally include zoledronic acid on their formularies for osteoporosis when oral bisphosphonates have failed or are contraindicated. Expect a prior authorization requirement. Typical commercial copays range from $50 to $300 per infusion depending on your plan's specialty drug tier and whether you have met your deductible.

Prior Authorization Tips

Prior authorization for zoledronic acid usually requires documentation of: a DXA scan showing a T-score of −2.5 or below (or −1.0 to −2.5 with FRAX-calculated 10-year major osteoporotic fracture risk ≥20%), trial of or contraindication to at least one oral bisphosphonate, and confirmation that the infusion will be administered in a medically supervised setting. According to the Endocrine Society's 2020 clinical practice guideline [3], IV bisphosphonates are appropriate when oral agents are not tolerated or when adherence concerns are documented.

503A Compounded Zoledronic Acid in North Dakota

Compounded zoledronic acid is legally available in North Dakota through licensed 503A pharmacies. A 503A pharmacy compounds medications pursuant to individual patient prescriptions under Section 503A of the Federal Food, Drug, and Cosmetic Act.

What This Means in Practice

A 503A compounding pharmacy can prepare zoledronic acid for a specific patient if a licensed prescriber writes the order. This route may reduce cost compared to commercial products, though the price depends heavily on the individual pharmacy. Some 503A pharmacies have quoted significantly lower prices than the $600 retail average for the commercial generic.

Quality and Safety Considerations

The FDA's guidance on 503A compounding [4] requires that compounded drugs meet state board of pharmacy standards but does not require FDA preapproval. The North Dakota Board of Pharmacy oversees 503A facilities operating within the state. Patients should confirm that any compounding pharmacy holds a current ND state license and follows USP 797 sterile compounding standards, which is especially relevant for an IV product like zoledronic acid.

Dr. Bart Clarke, an endocrinologist at Mayo Clinic who has published extensively on bisphosphonate therapy, has stated: "For intravenous bisphosphonates, the sterility and stability of the compounded product are non-negotiable. Patients should ask their pharmacy about USP 797 compliance and beyond-use dating before proceeding" [5].

Telehealth Prescribing of Reclast in North Dakota

North Dakota permits telehealth prescribing of zoledronic acid. A provider can evaluate you via video visit, order the necessary pre-infusion labs (serum calcium, creatinine, estimated GFR, 25-hydroxyvitamin D), and write the prescription. The infusion itself must still occur in person at a licensed infusion center, physician office, or hospital outpatient department.

How the Telehealth Workflow Operates

1. Complete a video consultation with a licensed prescriber (MD, DO, NP, or PA with prescriptive authority in North Dakota).
2. The prescriber orders baseline labs and a DXA scan if not recently completed.
3. Once labs confirm eligibility (eGFR ≥35 mL/min, corrected calcium within normal range), the prescriber sends the zoledronic acid order to an infusion site.
4. You receive the 15-minute IV infusion at the designated facility.
5. Post-infusion monitoring for acute phase reactions (fever, myalgia, arthralgia) occurs for 30 to 60 minutes on-site.

The American Association of Clinical Endocrinology (AACE) 2020 postmenopausal osteoporosis guideline [6] supports telehealth-initiated osteoporosis management when in-person components (DXA, infusion) are completed at qualified facilities.

Discount Programs and Savings Strategies

Several programs can reduce out-of-pocket cost for North Dakota residents who do not have adequate insurance coverage for zoledronic acid.

Novartis Patient Assistance Program

Novartis operates the Reclast Patient Assistance Program for uninsured patients. Income eligibility thresholds are typically set at or below 400% of the federal poverty level ($62,400 for a single individual in 2026). Approved patients receive the drug at no cost. Application requires prescriber involvement and income documentation.

Generic Manufacturer Copay Cards

Several generic zoledronic acid manufacturers offer copay assistance cards that can reduce the patient's share by $100 to $300 per infusion for commercially insured patients. These cards do not apply to government insurance (Medicare, Medicaid, Tricare). Check with your specific generic manufacturer (Mylan/Viatris, Hospira/Pfizer, Apotex) for current program terms.

GoodRx and Similar Aggregators

Pharmacy discount aggregators like GoodRx can display cash-pay pricing at participating North Dakota pharmacies and infusion centers. Prices fluctuate, but these platforms sometimes surface rates below the $600 state average by routing to specific pharmacy benefit managers.

340B-Eligible Facilities

As noted above, if you receive care at a 340B-covered entity (such as a federally qualified health center or disproportionate share hospital), the facility purchases the drug at a steep discount and may pass savings to uninsured or underinsured patients. North Dakota has several 340B-registered entities [7] concentrated in Fargo, Bismarck, Grand Forks, and Minot.

Clinical Considerations Before Your Infusion

Zoledronic acid is not appropriate for everyone. Pre-infusion screening matters.

Renal Function

The FDA-approved labeling [8] contraindicates zoledronic acid in patients with creatinine clearance <35 mL/min. A post-hoc analysis of the HORIZON-PFT trial found that patients with baseline eGFR 35 to 60 mL/min did not experience significantly higher rates of renal adverse events compared with those with eGFR >60 mL/min, but close monitoring was required (Boonen et al., JBMR 2008) [9].

Hypocalcemia

Serum calcium must be corrected before infusion. Patients with vitamin D deficiency (25-OH-D <20 ng/mL) should receive supplementation for at least two weeks before the infusion to prevent symptomatic hypocalcemia. The Endocrine Society recommends maintaining 25-OH-D levels of 30 to 50 ng/mL in osteoporosis patients (Holick et al., JCEM 2011) [10].

Acute Phase Reaction

Roughly 30% of first-time recipients experience flu-like symptoms (fever, myalgia, headache) within 24 to 72 hours of infusion. This rate drops to about 7% with subsequent annual infusions [1]. Acetaminophen or ibuprofen taken before and after the infusion can reduce symptom severity.

Dental Screening

Osteonecrosis of the jaw (ONJ) is rare with annual IV bisphosphonate dosing (estimated incidence: 1 in 10,000 to 1 in 100,000 patient-years for osteoporosis doses), but a dental examination before initiating therapy is recommended by the American Dental Association and the AACE guideline [6]. Any invasive dental procedures should be completed before the first infusion.

How North Dakota Compares to Neighboring States

Cash-pay pricing for zoledronic acid varies across the upper Midwest. North Dakota's $600 average sits near the regional median. Minnesota retail pharmacies average $550 to $650, while Montana and South Dakota tend to run $575 to $625. The main variable is not state-level regulation but the density of infusion centers and whether a hospital outpatient department or independent office administers the drug.

South Dakota Medicaid covers zoledronic acid with prior authorization, which creates a coverage gap for North Dakota Medicaid enrollees who might otherwise qualify in a neighboring state. This distinction matters for patients living near state borders (Wahpeton-Breckenridge, Fargo-Moorhead) who might consider cross-state care.